Trial Profile
Nab-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Capecitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms LAPACT
- Sponsors Celgene Corporation
- 29 May 2018 Status changed from active, no longer recruiting to completed.
- 24 Apr 2018 Planned End Date changed from 15 Jun 2018 to 26 Apr 2018.
- 20 Jan 2018 Results (n=106) assessing the efficacy and safety of an induction phase regimen of nab-paclitaxel + Gemcitabine in previously untreated patients with locally advanced pancreatic cancer, presented at the 2018 Gastrointestinal Cancers Symposium.